EpimAb Biotherapeutics’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Epimab Biotherapeutics develops novel bi-specific antibody therapeutics for the treatment of cancer, inflammatory and autoimmune diseases. Read more

2 Followers on Owler
2 Followers on Owler
2 Followers on Owler
2 Followers on Owler

Epimab Biotherapeutics develops novel bi-specific antibody therapeutics for the treatment of cancer, inflammatory and autoimmune diseases. Read more

Chengbin Wu's photo - CEO of EpimAb Biotherapeutics

CEO

Chengbin Wu

CEO Approval Rating

82/100

Founded:

2015

Status:

PrivateIndependent Company

Est. Annual Revenue
Est. Employees
Sector

Update Industry

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Genmab is perceived as one of EpimAb Biotherapeutics's biggest rivals. Genmab's headquarters is in Copenhagen, Capital Region, and was founded in 1999. Genmab operates in the Biotechnology industry. Genmab generates 9,115% of EpimAb Biotherapeutics's revenue.

ADC Therapeutics has been one of EpimAb Biotherapeutics's top competitors. ADC Therapeutics is a Public company that was founded in 2011 in Epalinges, Vaud. ADC Therapeutics is in the Biotechnology field. Compared to EpimAb Biotherapeutics, ADC Therapeutics has 92 more employees.

MorphoSys is EpimAb Biotherapeutics's #3 rival. MorphoSys was founded in Planegg, Bavaria} in 1992. MorphoSys operates in the Biotechnology industry. Compared to EpimAb Biotherapeutics, MorphoSys generates $71.1M more revenue.

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is 46 a good estimate for EpimAb Biotherapeutics's Employee count?

Acquisitions

No recent acquisitions found related to EpimAb Biotherapeutics

EpimAb Biotherapeutics Funding History

$25M$99M

Since EpimAb Biotherapeutics was founded in 2015, it has participated in 2 rounds of funding. In total EpimAb Biotherapeutics has raised $99.0M. EpimAb Biotherapeutics' last funding round was on Jun 2019 for a total of $74.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Series B
Jun 2019
$74M

SDIC Fund

Series A
Apr 2017
$25M

Since EpimAb Biotherapeutics was founded in 2015, it has participated in 2 rounds of funding. In total EpimAb Biotherapeutics has raised $99.0M. EpimAb Biotherapeutics' last funding round was on Jun 2019 for a total of $74.0M

Investments

No recent investments found related to EpimAb Biotherapeutics

EpimAb Biotherapeutics News

April 23, 2020BioSpace

EpimAb Biotherapeutics and QIMR Berghofer Medical Research Institute Announce Research Collaboration and License Agreement on Novel Bispecific Target Combinations

EpimAb receives exclusive access to newly discovered target combinations in order to expand its propr... See more »
April 23, 2020firstwordpharma

EpimAb Biotherapeutics and QIMR Berghofer Medical Research Institute Announce Research Collaboration and License Agreement on Novel Bispecific Target Combinations

SHANGHAI & BRISBANE, Australia--(BUSINESS WIRE)-- EpimAb Biotherapeutics, an emerging Shanghai-based ... See more »
June 6, 2019Finance Asia

EpimAb Biotherapeutics bags $74m amid cancer drug boom

The Shanghai-based biopharmaceutical startup is the latest to raise capital from private investors as... See more »
April 26, 2019Pharmabiz

EpimAb Biotherapeutics' core bispecific antibody technology receives US patent

EpimAb Biotherapeutics, an emerging biopharmaceutical company based in Shanghai, announced that the U... See more »
January 29, 2019PharmiWeb

EpimAb Biotherapeutics Achieves Key Milestone with Lead Cancer Program EMB01

EpimAb Biotherapeutics Achieves Key Milestone with Lead Cancer Program EMB01EpimAb Biotherap...EpimAb... See more »
September 17, 2018Pharmabiz

EpimAb seeks US & Chinese approvals for EMB01 to treat solid tumors with novel bispecific antibody

EpimAb Biotherapeutics, an emerging Shanghai─based biopharmaceutical company specializing in bispecif... See more »
April 24, 2018The Pharma Letter

BRIEF-EpimAb and Zhejiang Teruisi ink collaboration

Shanghai's EpimAb Biotherapeutics and Zhejiang Teruisi Biopharmaceutical will join forces on a bispec... See more »

EpimAb Biotherapeutics Blogs

October 21, 2020Epimab Biotherapeutics Blog

Upstream Cell Line Development Engineer / Assistant Engineer

岗位名称:上游细胞株筛选助理工程师/工程师 Position: Upstream Cell Line Development Engineer / Assistant Engineer Location... See more »
September 21, 2020Epimab Biotherapeutics Blog

Convenient Advice For Thesis Statement Help In The USA

A thesis statement is one sentence that expresses the primary thought of a research paper or essay, r... See more »
September 20, 2020Epimab Biotherapeutics Blog

Comparing Significant Criteria In ultius

Is likely one of the numerous writing providers which claims that they will enable you to write down ... See more »
September 20, 2020Epimab Biotherapeutics Blog

A Background In Realistic Systems Of Cheapest Essay Writing Service

Our main writing service gives customized written papers in 80+ disciplines. It is normal to really f... See more »
September 19, 2020Epimab Biotherapeutics Blog

Simplifying No-Hassle essayusa review Systems

EssayUSA is a writing service based mostly in the United States. Customer service is immortal when de... See more »
September 19, 2020Epimab Biotherapeutics Blog

The Facts On Necessary Details In Victoria Brides Review

You will make a higher first impression – and increase your odds of a reply – if you ignore her look ... See more »
September 17, 2020Epimab Biotherapeutics Blog

The Key Life Of Best Essay Writing Services

Place anonymous order and get professional assist from tutorial writers. Be sure to present a map, by... See more »

Social Media

Headquarters

Gartenstraße 8

Warmsroth, Rhineland-Palatinate55442

49-15226107621

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Epimab Biotherapeutics develops novel bi-specific antibody therapeutics for the treatment of cancer, inflammatory and autoimmune diseases. EpimAb Biotherapeutics was founded in 2015. EpimAb Biotherapeutics' headquarters is located in Warmsroth, Rhinel...

CEO

EpimAb Biotherapeutics's CEO, Chengbin Wu, currently has an approval rating of 82%. EpimAb Biotherapeutics's primary competitors are Genmab, ADC Therapeutics & MorphoSys.

Website

epimab.com

Frequently Asked Questions about EpimAb Biotherapeutics

  1. When was EpimAb Biotherapeutics founded?

    EpimAb Biotherapeutics was founded in 2015
  2. Who is EpimAb Biotherapeutics's CEO?

    EpimAb Biotherapeutics's CEO is Chengbin Wu
  3. How much revenue does EpimAb Biotherapeutics generate?

    EpimAb Biotherapeutics generates $9.3M in revenue
  4. How much funding does EpimAb Biotherapeutics have?

    EpimAb Biotherapeutics has historically raised $99M in funding
  1. Where is EpimAb Biotherapeutics's headquarters?

    EpimAb Biotherapeutics's headquarters is in Warmsroth Rhineland-Palatinate, DE
  2. How many employees does EpimAb Biotherapeutics have?

    EpimAb Biotherapeutics has 46 employees
  3. Who are EpimAb Biotherapeutics's competitors?

    EpimAb Biotherapeutics's top competitors are Genmab, ADC Therapeutics, MorphoSys